Vitiligo trials of SCENESSE® – Lee Thomas and Dr Philippe Wolgen, Part 2
Taking on Vitiligo, a depigmentation disorder of the skin.
In 2010, CLINUVEL ventured into an area of dermatology where no other pharmaceutical company has yet succeeded, trialing a new drug, SCENESSE® (afamelanotide) in vitiligo as a combination therapy with narrowband ultraviolet B light therapy.
Winner of four Emmy® Awards, anchor and producer, entertainment reporter at WJBK Fox 2 Detroit, Mr Lee Thomas is a spokesperson for the US vitiligo community.
In this four part video series, shot in early 2012, he interrogated CLINUVEL’s CEO Dr Philippe Wolgen about SCENESSE® as a potential remedy in vitiligo.
Learn more about CLINUVEL’s vitiligo program.